Noam Shoresh

Noam Shoresh

Auto-generated profile, based on publicly available information

Noam Shoresh

Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Science
Verified
Journal Article
Closed access
PDF file
KYKeren Yizhak
Keren Yizhak
FAFrançois Aguet
François Aguet
JKJaegil Kim
Jaegil Kim
JHJulian M. Hess
Julian M. Hess
KKKirsten Kübler
Kirsten Kübler
GGGad Getz
Gad Getz
Somatic mosaicism in normal tissues: Somatic cells can accumulate mutations over the course of an individual's lifetime. This generates cells that differ genetically at specific loci within the genome. To explore how this genetic diversity in individuals contributes to disease, Yizhak et al. developed a method to detect mutations from RNA sequencing data (see the Perspective by Tomasetti). Applying this method to Cancer Genome Atlas samples and normal samples from the Genotype-Tissue Expression (GTEx) project generated a tissue-specific study of mutation accumulation. Somatic mutations were detected in nearly all individuals and across many normal human tissues in genomic regions called cancer hotspots and in genes that play a role in cancer. Interestingly, the skin, lung, and esophagus exhibited the most mutations, suggesting that the environment generates many human mutations. Science , this issue p. eaaw0726 ; see also p. 938

17 March 2006 in Science
Verified
Journal Article
Closed access
PDF file
MHMatthew Hegreness
Matthew Hegreness
NSNoam Shoresh
Noam Shoresh
DHDaniel Hartl
Daniel Hartl
RKRoy Kishony
Roy Kishony
Rapid evolution of asexual populations, such as that of cancer cells or of microorganisms developing drug resistance, can include the simultaneous spread of distinct beneficial mutations. We demonstrate that evolution in such cases is driven by the fitness effects and appearance times of only a small minority of favorable mutations. The complexity of the mutation-selection process is thereby greatly reduced, and much of the evolutionary dynamics can be encapsulated in two parameters—an effective selection coefficient and effective rate of beneficial mutations. We confirm this theoretical finding and estimate the effective parameters for evolving populations of fluorescently labeledEscherichia coli. The effective parameters constitute a simple description and provide a natural standard for comparing adaptation between species and across environments.

29 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NJNauman Javed
Nauman Javed
YFYossi Farjoun
Yossi Farjoun
TFTim J. Fennell
Tim J. Fennell
CECharles B. Epstein
Charles B. Epstein
BBBradley E. Bernstein
Bradley E. Bernstein
NSNoam Shoresh
Noam Shoresh
As the number of genomics datasets grows rapidly, sample mislabeling has become a high stakes issue. We present CrosscheckFingerprints (Crosscheck), a tool for quantifying sample-relatedness and detecting incorrectly paired sequencing datasets from different donors. Crosscheck outperforms similar methods and is effective even when data are sparse or from different assays. Application of Crosscheck to 8851 ENCODE ChIP-, RNA-, and DNase-seq datasets enabled us to identify and correct dozens of mislabeled samples and ambiguous metadata annotations, representing ~1% of ENCODE datasets.

4 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMolly M. Moore
Molly M. Moore
SWSiddarth Wekhande
Siddarth Wekhande
RIRobbyn Issner
Robbyn Issner
ACAlejandro Collins
Alejandro Collins
ACAnna J. Cruz
Anna J. Cruz
FNFadi J. Najm
Fadi J. Najm
A critical goal in functional genomics is evaluating which non-coding elements contribute to gene expression, cellular function, and disease. Functional characterization remains a challenge due to the abundance and complexity of candidate elements. Here, we develop a CRISPRi-based approach for multi-locus screening of putative transcription factor binding sites with a single truncated guide. A truncated guide with hundreds of sequence match sites can reliably disrupt enhancer activity, which expands the targeting scope of CRISPRi while maintaining repressive efficacy. We screen over 13,000 possible CTCF binding sites with 24 guides at 10 nucleotides in spacer length. These truncated guides direct CRISPRi-mediated deposition of repressive H3K9me3 marks and disrupt transcription factor binding at most sequence match target sites. This approach can be a valuable screening step for testing transcription factor binding motifs or other repeated genomic sequences and is easily implemented with existing tools.

20 October 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
VHVivian Hecht
Vivian Hecht
KDKevin Dong
Kevin Dong
SRSreshtaa Rajesh
Sreshtaa Rajesh
PSPolina Shpilker
Polina Shpilker
SWSiddarth Wekhande
Siddarth Wekhande
NSNoam Shoresh
Noam Shoresh
Histone ChIP-seq is one of the primary methods for charting the cellular epigenomic landscape, the components of which play a critical regulatory role in gene expression. Analyzing the activity of regulatory elements across datasets and cell types can be challenging due to shifting peak positions and normalization artifacts resulting from, for example, differing read depths, ChIP efficiencies, and target sizes. Moreover, broad regions of enrichment seen in repressive histone marks often evade detection by commonly used peak callers. Here, we present a simple and versatile method for identifying enriched regions in ChIP-seq data that relies on estimating a gamma distribution fit to non-overlapping 5kB genomic bins to establish a global background. We use this distribution to assign a probability of being signal (PBS) between zero and one to each 5 kB bin. This approach, while lower in resolution than typical peak-calling methods, provides a straightforward way to identify enriched regions and compare enrichments among multiple datasets, by transforming the data to values that are universally normalized and can be readily visualized and integrated with downstream analysis methods. We demonstrate applications of PBS for both broad and narrow histone marks, and provide several illustrations of biological insights which can be gleaned by integrating PBS scores with downstream data types.

21 August 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
BPBradley E. Poulsen
Bradley E. Poulsen
RYRui Yang
Rui Yang
ACAnne E. Clatworthy
Anne E. Clatworthy
TWTiantian White
Tiantian White
SOSarah J. Osmulski
Sarah J. Osmulski
DHDeborah T. Hung
Deborah T. Hung
Genomics offered the promise of transforming antibiotic discovery by revealing many new essential genes as good targets, but the results fell short of the promise. It is becoming clear that a major limitation was that essential genes for a bacterial species were often defined based on a single or limited number of strains grown under a single or limited number of in vitro laboratory conditions. In fact, the essentiality of a gene can depend on both genetic background and growth condition. We thus developed a strategy for more rigorously defining the core essential genome of a bacterial species by studying many pathogen strains and growth conditions. We assessed how many strains must be examined to converge on a set of core essential genes for a species. We used transposon insertion sequencing (Tn-Seq) to define essential genes in nine strains of Pseudomonas aeruginosa on five different media and developed a novel statistical model, FiTnEss , to classify genes as essential versus non-essential across all strain-media combinations. We defined a set of 321 core essential genes, representing 6.6% of the genome. We determined that analysis of 4 strains was typically sufficient in P. aeruginosa to converge on a set of core essential genes likely to be essential across the species across a wide range of conditions relevant to in vivo infection, and thus to represent attractive targets for novel drug discovery.